The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ

Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl

The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7

EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ

In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow

The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO

#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8